Endobronchial Ultrasound Biopsy Market Size, Share, Growth, and Industry Analysis, By Type (EBUS-TBNA,Bronchoscopes and probes,Biopsy forceps and needles,Ultrasound processor and needles,Cytology brushes and spray catheter,Others), By Application (Hospitals,Specialty Centers,Diagnostic Centers,Ambulatory Surgical Centers), Regional Insights and Forecast to 2035

Endobronchial Ultrasound Biopsy Market Overview

The global Endobronchial Ultrasound Biopsy Market size is projected to grow from USD 726.19 million in 2026 and reaching USD 1442.02 million by 2035, expanding at a CAGR of 7.92% during the forecast period.

The Endobronchial Ultrasound Biopsy Market is developing as respiratory disease screening, lung cancer diagnosis, and minimally invasive tissue sampling become increasingly important across modern healthcare systems. EBUS-guided biopsy combines real-time ultrasound imaging with bronchoscopic navigation, enabling clinicians to evaluate mediastinal and hilar lymph nodes while reducing dependence on more invasive diagnostic procedures. In 2026, Hospitals are expected to represent the largest application segment, supported by advanced pulmonary departments, multidisciplinary oncology teams, and access to anesthesia and pathology services. Approximately 58% of major tertiary hospitals in developed healthcare markets are estimated to have access to advanced bronchoscopy capabilities, creating a strong installed base for EBUS-related procedures.

In the United States, demand is being supported by higher awareness of early lung cancer diagnosis, increasing utilization of image-guided biopsy, and expansion of specialized pulmonary and thoracic oncology services. Approximately 46% of major U.S. hospitals are estimated to operate structured interventional pulmonology or advanced bronchoscopy programs, while EBUS-TBNA is increasingly incorporated into diagnostic pathways requiring mediastinal staging. Through 2035, demand should benefit from continued improvements in ultrasound processors, bronchoscopes and probes, biopsy forceps and needles, cytology brushes and spray catheter systems, and workflow integration across Hospitals, Specialty Centers, Diagnostic Centers, and Ambulatory Surgical Centers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Rising demand for minimally invasive lung cancer diagnosis is accelerating EBUS adoption, with approximately 46% of major U.S. hospitals estimated to operate advanced bronchoscopy programs supporting image-guided biopsy workflows.
• Major Market Restraint: High equipment costs and specialist training requirements restrict adoption in smaller facilities, with approximately 37% of lower-volume hospitals estimated to lack dedicated advanced bronchoscopy infrastructure.
• Emerging Trends: Real-time ultrasound imaging, improved needle design, and navigation-assisted bronchoscopy are reshaping procedures, with approximately 41% of advanced pulmonary centers estimated to use enhanced image-guided workflows.
• Regional Leadership: North America is expected to lead the market, supported by mature pulmonary-care infrastructure and approximately 39% of global demand concentrated in the region during 2026.
• Competitive Landscape: Manufacturers are emphasizing integrated bronchoscopy platforms and disposable biopsy components, with approximately 24% of recent product-development activity focused on improving visualization, sampling, or procedural workflow.
• Market Segmentation: EBUS-TBNA is expected to remain the leading product type with approximately 42% share in 2026, while Hospitals should dominate applications at roughly 54% due to complex diagnostic infrastructure.
• Recent Development: Adoption of compact ultrasound processors and improved sampling needles is increasing procedural flexibility, with approximately 18% of new advanced bronchoscopy installations estimated to prioritize upgraded imaging and biopsy capabilities.

Latest Trends

Technological development in the Endobronchial Ultrasound Biopsy Market is increasingly focused on improving visualization, tissue acquisition, procedural consistency, and physician control. Modern EBUS platforms combine high-resolution ultrasound with flexible bronchoscopic systems, allowing clinicians to identify lymph-node structures and perform targeted sampling during a single procedure. Approximately 41% of advanced pulmonary centers are estimated to use enhanced image-guided workflows, reflecting the movement toward more precise diagnostic pathways. Manufacturers are also improving biopsy needles, ultrasound probes, and processor interfaces to reduce unnecessary procedural steps and improve compatibility across clinical environments.

Another important trend is the integration of EBUS with broader lung cancer diagnostic and staging pathways. Approximately 35% of multidisciplinary thoracic oncology programs are estimated to coordinate bronchoscopy, pathology, imaging, and oncology decision-making within a unified workflow. Disposable or semi-disposable components are gaining attention because they can simplify reprocessing requirements and support infection-control procedures. Diagnostic Centers and Specialty Centers are also increasingly adopting compact systems where procedure volume justifies investment. Through 2035, greater emphasis on early diagnosis, molecular testing requirements, smaller biopsy targets, and efficient tissue acquisition should encourage continued innovation across EBUS-TBNA, bronchoscopes and probes, biopsy forceps and needles, ultrasound processor and needles, and cytology brushes and spray catheter systems.

Market Dynamics

Driver

"Growing demand for minimally invasive pulmonary diagnosis."

The primary growth driver is the increasing preference for minimally invasive approaches to lung cancer diagnosis and mediastinal lymph-node assessment. EBUS allows physicians to visualize structures adjacent to the airway while obtaining tissue during the same procedure, reducing the need for more invasive diagnostic pathways in appropriately selected patients. Approximately 46% of major U.S. hospitals are estimated to operate advanced bronchoscopy programs in 2026, creating a substantial clinical base for EBUS utilization.

Growing lung cancer screening activity is also supporting procedure volumes because abnormal imaging findings frequently require tissue confirmation or staging. Approximately 32% of high-volume pulmonary centers are estimated to have expanded their diagnostic bronchoscopy capacity during the past several years. EBUS-TBNA remains particularly important because it can provide cytological and tissue samples from mediastinal and hilar lymph nodes. As clinical teams seek faster diagnostic pathways, hospitals are increasingly prioritizing systems that combine visualization, sampling, and procedural efficiency within a single platform.

Restraint

"Capital requirements and specialist expertise limit wider adoption."

The cost of advanced bronchoscopy systems remains a significant barrier, particularly for lower-volume hospitals and facilities in developing healthcare markets. An EBUS program can require ultrasound processors, bronchoscopes, probes, biopsy accessories, pathology support, maintenance, and specialized training. Approximately 37% of lower-volume hospitals are estimated to lack dedicated advanced bronchoscopy infrastructure, limiting their ability to perform EBUS procedures independently.

Training requirements represent another constraint because accurate ultrasound interpretation, airway navigation, needle positioning, sample handling, and complication management require specialized expertise. Approximately 29% of facilities introducing advanced bronchoscopy services are estimated to require structured physician training before reaching routine procedural capacity. In addition, reimbursement differences between regions can affect investment decisions. These factors can slow adoption even when clinical demand is increasing, particularly in Diagnostic Centers and Ambulatory Surgical Centers with limited procedure volumes.

Opportunity

"Expansion of specialized pulmonary diagnostics creates new demand."

The expansion of specialized pulmonary and thoracic oncology services provides significant opportunity for EBUS manufacturers. As more healthcare systems establish multidisciplinary pathways for lung cancer diagnosis and staging, demand for accurate minimally invasive sampling is increasing. Approximately 35% of multidisciplinary thoracic oncology programs are estimated to integrate bronchoscopy, pathology, and imaging within coordinated diagnostic workflows, creating opportunities for equipment suppliers and accessory manufacturers.

Emerging markets offer additional potential because advanced bronchoscopy penetration remains below levels observed in North America and Europe. Approximately 24% of major hospitals in selected developing healthcare markets are estimated to have access to advanced EBUS capabilities, leaving considerable room for infrastructure expansion. Compact ultrasound processors, simplified workflow systems, and cost-efficient biopsy accessories can help broaden adoption. Ambulatory Surgical Centers and Diagnostic Centers may also represent growing opportunities as procedure pathways become more standardized and selected cases move toward shorter-stay environments.

Challenge

"Complex procedures require consistent expertise and workflow coordination."

Maintaining consistent procedural quality is a major challenge because EBUS performance depends on operator experience, ultrasound interpretation, airway access, needle positioning, and appropriate specimen handling. Approximately 26% of newly established advanced bronchoscopy programs are estimated to experience an initial learning period before achieving stable procedural throughput. Variability in physician experience can affect sampling adequacy and procedure time.

Another challenge involves coordinating equipment, biopsy accessories, pathology services, and infection-control processes. Approximately 31% of advanced bronchoscopy facilities are estimated to use multiple accessory categories during routine EBUS workflows, increasing the importance of inventory planning and compatibility. Manufacturers must therefore balance technological sophistication with usability. Systems that reduce setup time, simplify probe handling, improve visualization, and support reliable tissue acquisition can gain an advantage as hospitals seek predictable clinical workflows.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

By Types

EBUS-TBNA: EBUS-TBNA is expected to remain the largest product category, accounting for approximately 42% of global market demand in 2026. Its importance is linked to the ability to obtain tissue from mediastinal and hilar lymph nodes under real-time ultrasound guidance. Hospitals and Specialty Centers continue to represent the strongest users because these facilities manage complex pulmonary and Precision oncology cases. EBUS-TBNA systems are increasingly designed around improved needle control, visualization, and specimen acquisition. Approximately 49% of advanced pulmonary centers are estimated to use EBUS-TBNA as part of routine mediastinal diagnostic workflows.

Bronchoscopes and probes: Bronchoscopes and probes are projected to represent approximately 19% of the market in 2026 and remain fundamental to EBUS procedures because they provide airway access and imaging. Product development is focused on improved maneuverability, smaller insertion profiles, image quality, and compatibility with ultrasound components. Approximately 34% of newly installed advanced bronchoscopy platforms are estimated to prioritize enhanced scope maneuverability or visualization. Growth should remain closely connected with expansion of EBUS programs, replacement cycles, and the modernization of pulmonary procedure rooms.

Biopsy forceps and needles: Biopsy forceps and needles are expected to hold approximately 14% market share in 2026, supported by recurring procedural consumption and the need for reliable tissue acquisition. Improvements in needle sharpness, flexibility, sampling capacity, and deployment control are helping physicians obtain adequate specimens from challenging targets. Approximately 38% of advanced bronchoscopy programs are estimated to evaluate biopsy accessory performance when upgrading EBUS equipment. Recurring demand from Hospitals and Specialty Centers provides an important replacement and consumables component within the market.

Ultrasound processor and needles: Ultrasound processor and needles are projected to account for approximately 11% of market demand in 2026. Processors increasingly provide higher-resolution imaging and improved visualization of structures surrounding the airway, while compatible needles support targeted sampling. Approximately 27% of new EBUS installations are estimated to include upgraded ultrasound processing capabilities. Continued development of compact processors and more intuitive interfaces should support adoption in Diagnostic Centers and Ambulatory Surgical Centers where space and workflow efficiency are important purchasing considerations.

Cytology brushes and spray catheter: Cytology brushes and spray catheter products are expected to represent approximately 8% of the market in 2026. These accessories support complementary sampling and airway diagnostic workflows, particularly when clinicians require additional cellular material or localized assessment. Approximately 21% of advanced bronchoscopy procedures are estimated to involve complementary sampling accessories depending on clinical requirements. Their recurring-use characteristics can provide stable demand even when capital-equipment purchasing cycles fluctuate.

Others: Other products are estimated to account for approximately 6% of market demand in 2026 and include supporting components and specialized accessories used within advanced bronchoscopy workflows. Demand is influenced by procedure complexity, institutional preferences, and the increasing standardization of EBUS services. Approximately 17% of advanced centers are estimated to use specialized accessories beyond core biopsy equipment for selected procedures. Innovation in this segment is likely to focus on workflow support, compatibility, specimen handling, and procedural efficiency through 2035.

By Applications

Hospitals: Hospitals are expected to remain the dominant application, accounting for approximately 54% of global market demand in 2026. Their leadership reflects access to advanced imaging, pulmonary specialists, thoracic oncology teams, pathology laboratories, anesthesia services, and emergency support. Approximately 58% of major tertiary hospitals in developed healthcare markets are estimated to maintain advanced bronchoscopy capabilities. Hospitals also manage a larger proportion of complex diagnostic cases, making them important purchasers of EBUS platforms and associated biopsy accessories.

Hospital adoption is additionally supported by the increasing integration of lung cancer diagnosis and staging into multidisciplinary care pathways. Approximately 35% of major thoracic oncology programs are estimated to coordinate EBUS procedures with imaging and pathology teams. This integrated model can shorten diagnostic workflows and support treatment planning. Through 2035, hospitals should continue to generate the largest share of demand as healthcare systems expand interventional pulmonology programs and replace older bronchoscopy equipment with higher-resolution systems.

Specialty Centers: Specialty Centers are projected to account for approximately 24% of market demand in 2026, supported by concentrated expertise in pulmonary medicine, thoracic oncology, and interventional bronchoscopy. Approximately 47% of high-volume specialty centers are estimated to provide advanced bronchoscopic procedures. These facilities often maintain experienced procedural teams capable of handling complex sampling and staging cases, creating favorable conditions for adoption of sophisticated EBUS platforms.

Specialty Centers are also early adopters of technologies that improve procedural precision and workflow efficiency. Approximately 39% of specialty pulmonary centers are estimated to evaluate new imaging, navigation, or sampling technologies as part of equipment modernization. Their concentrated case volumes can justify investments in advanced ultrasound processors, dedicated scopes, and specialized biopsy accessories. Through 2035, growth should be supported by increasing referral volumes and greater concentration of complex pulmonary diagnostics within specialist facilities.

Diagnostic Centers: Diagnostic Centers are expected to represent approximately 13% of the market in 2026. Their role is expanding as healthcare systems seek faster diagnostic services outside traditional hospital environments. Approximately 28% of major diagnostic networks are estimated to offer some form of advanced pulmonary diagnostic service, although EBUS availability remains more limited than conventional imaging or laboratory testing. Compact systems and simplified workflows could improve the commercial attractiveness of EBUS within this application.

Diagnostic Centers are increasingly focused on procedure efficiency, patient throughput, and standardized sample handling. Approximately 23% of centers considering advanced bronchoscopy expansion are estimated to prioritize compact equipment and streamlined workflows. As physician availability improves and referral networks expand, selected Diagnostic Centers may increase EBUS capacity. Growth will nevertheless depend on procedure volume, reimbursement, access to pathology services, and the availability of trained bronchoscopists.

Ambulatory Surgical Centers: Ambulatory Surgical Centers are projected to account for approximately 9% of market demand in 2026, representing the smallest supplied application category but an emerging opportunity. Approximately 16% of advanced Ambulatory Surgical Centers are estimated to evaluate bronchoscopy services involving shorter-stay diagnostic procedures. Adoption is supported by improvements in equipment size, procedural standardization, and recovery pathways.

Growth in Ambulatory Surgical Centers will depend on careful patient selection and the availability of appropriate anesthesia, pathology, infection-control, and emergency-support capabilities. Approximately 12% of eligible procedures are estimated to have potential for outpatient or short-stay management where clinical protocols permit. As EBUS systems become more compact and workflow requirements become easier to manage, selected Ambulatory Surgical Centers should increase participation in pulmonary diagnostic services through 2035.

Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America is expected to maintain the leading position in the Endobronchial Ultrasound Biopsy Market, accounting for approximately 39% of global demand in 2026. The region benefits from established interventional pulmonology programs, high lung cancer diagnostic activity, advanced hospital infrastructure, and strong adoption of minimally invasive biopsy technologies. Approximately 46% of major U.S. hospitals are estimated to operate advanced bronchoscopy programs, providing a substantial installed base for EBUS equipment.

The United States remains the principal regional contributor because thoracic oncology programs increasingly integrate EBUS into diagnostic and staging workflows. Approximately 35% of major multidisciplinary thoracic oncology programs are estimated to coordinate bronchoscopy with pathology and imaging services. Canada also contributes through specialized respiratory-care centers and expanding minimally invasive diagnostic capabilities. Through 2035, North American demand should remain supported by lung cancer screening, replacement of older equipment, improved biopsy accessories, and continued development of image-guided pulmonary procedures.

Europe

Europe is projected to account for approximately 31% of global Endobronchial Ultrasound Biopsy Market demand in 2026. Germany, the United Kingdom, France, Italy, and Spain represent important markets because of mature healthcare infrastructure and established respiratory medicine networks. Approximately 42% of major European tertiary hospitals are estimated to have advanced bronchoscopy capabilities, supporting continued EBUS adoption.

European healthcare systems are increasingly emphasizing efficient cancer diagnosis, standardized clinical pathways, and minimally invasive procedures. Approximately 33% of major pulmonary centers are estimated to incorporate EBUS within multidisciplinary lung cancer staging workflows. Demand for compact equipment and disposable biopsy components is also increasing as healthcare providers seek efficient infection-control and procedure-management practices. Through 2035, Europe should benefit from aging populations, persistent respiratory disease burden, technological modernization, and expansion of specialized pulmonary services.

Asia-Pacific

Asia-Pacific is expected to account for approximately 21% of global market demand in 2026 and should register strong expansion through 2035. China, Japan, South Korea, India, and Australia are important regional markets, supported by increasing healthcare expenditure, expanding tertiary hospitals, and growing awareness of advanced lung cancer diagnostics. Approximately 29% of major hospitals in leading Asian metropolitan markets are estimated to have advanced bronchoscopy capabilities.

Japan and South Korea have relatively mature adoption, while India and China provide substantial long-term expansion opportunities as specialized pulmonary services become more widely available. Approximately 24% of developing-market hospitals are estimated to have access to advanced EBUS capabilities, indicating significant penetration potential. Lower-cost platforms, compact ultrasound processors, physician training, and improved biopsy accessories should support market development. Through 2035, Asia-Pacific is expected to gain share as lung cancer diagnosis becomes more structured and advanced pulmonary infrastructure expands.

Middle East and Africa

Middle East and Africa is projected to represent approximately 5% of global market demand in 2026. Adoption is concentrated in major tertiary hospitals and private healthcare networks where advanced pulmonary and oncology services are available. Approximately 22% of major hospitals in leading regional healthcare hubs are estimated to have advanced bronchoscopy capabilities, creating a developing market base.

Healthcare modernization, investment in specialized diagnostic centers, and increasing availability of trained respiratory specialists are supporting gradual adoption. Approximately 19% of major pulmonary facilities in the region are estimated to be expanding advanced diagnostic capabilities. However, equipment costs, training requirements, and uneven access to specialized pathology remain important considerations. Through 2035, market growth should be strongest in metropolitan healthcare systems where hospitals can support multidisciplinary lung cancer diagnosis and advanced bronchoscopy procedures.

Rest of World

Rest of World is expected to account for approximately 4% of global Endobronchial Ultrasound Biopsy Market demand in 2026, with Latin America and other developing healthcare markets contributing most of the activity. Approximately 18% of major hospitals in these markets are estimated to have advanced bronchoscopy capabilities, leaving substantial room for additional penetration.

Growth is supported by increasing private healthcare investment, specialist training, and expansion of diagnostic infrastructure. Approximately 16% of newly established pulmonary diagnostic programs are estimated to include advanced bronchoscopy capabilities within their development plans. Cost-efficient systems, compact processors, and standardized biopsy workflows can improve adoption where capital budgets remain constrained. Through 2035, Rest of World should experience gradual expansion as healthcare providers increase investment in lung cancer diagnosis and minimally invasive respiratory procedures.

List of Top Endobronchial Ultrasound Biopsy Market Companies

• Conmed Corporation
• Medtronic plc
• Olympus Corporation
• Fujifilm Corporation
• Boston Scientific Corporation
• Pentax Medical
• Cook Medical
• Veran Medical Technologies
• Medi-Globe GmbH
• Clinodevice

Top 2 Companies Market Share

• Olympus Corporation: Olympus Corporation maintains a leading competitive position in the Endobronchial Ultrasound Biopsy Market because of its extensive bronchoscopy portfolio, established hospital relationships, and broad respiratory-care infrastructure. The company is estimated to account for approximately 17% of global market demand in 2026. Its competitive strength is supported by integrated bronchoscopic visualization, ultrasound capabilities, biopsy accessories, and established physician familiarity. Continued investment in imaging quality, procedural workflow, and next-generation bronchoscopy should help the company maintain strong participation through 2035.
• Medtronic plc: Medtronic plc represents another major competitor, supported by its interventional pulmonology portfolio and established relationships across hospitals and specialty centers. The company is estimated to hold approximately 14% of global market demand in 2026. Its competitive strategy emphasizes image-guided procedures, navigation technologies, biopsy workflow, and integration with broader pulmonary diagnostic pathways. As clinicians increasingly seek efficient approaches for peripheral and mediastinal diagnosis, continued development of connected visualization and sampling technologies should support the company's market position.

Investment Analysis and Opportunities

Investment in the Endobronchial Ultrasound Biopsy Market is increasingly directed toward imaging quality, biopsy precision, procedural navigation, and equipment miniaturization. Approximately 44% of major product-development initiatives are estimated to target improvements in visualization, sampling, or procedural control. Manufacturers are also investing in ultrasound processors and compatible needles because higher-resolution imaging can help physicians identify anatomical structures and guide sampling more precisely.

Healthcare providers are allocating capital toward advanced bronchoscopy rooms, specialized scopes, pathology connectivity, and physician training. Approximately 31% of new advanced bronchoscopy program investments are estimated to include structured training or workflow-development components. Investment opportunities are particularly strong in Asia-Pacific and selected developing markets where EBUS penetration remains below mature-market levels. Ambulatory Surgical Centers and Diagnostic Centers may attract additional investment as compact systems and shorter-stay procedures improve the operational case for decentralized pulmonary diagnostics.

New Product Development

Product development is increasingly centered on smaller, more maneuverable bronchoscopes, improved ultrasound resolution, enhanced needle control, and integrated visualization. Manufacturers are working to simplify equipment interfaces while improving image clarity and procedural ergonomics. Approximately 26% of new product-development programs are estimated to prioritize equipment miniaturization or workflow simplification. These improvements can be particularly valuable in facilities where procedure-room space and staffing resources are constrained.

Biopsy accessories are also undergoing continuous refinement. Newer needles and sampling components are designed to improve penetration, tissue acquisition, and control while maintaining compatibility with flexible bronchoscopic systems. Approximately 38% of advanced bronchoscopy programs are estimated to review biopsy accessory performance when modernizing their EBUS capabilities. Future development should increasingly focus on combining high-resolution ultrasound, improved sampling, navigation assistance, and efficient specimen handling within coordinated procedural platforms.

Five Recent Developments

• January 2025 – Enhanced EBUS Imaging: Manufacturers increased development activity around higher-resolution ultrasound visualization and improved processor interfaces, with approximately 24% of new platform initiatives targeting imaging or visualization improvements.
• May 2025 – Biopsy Accessory Refinement: New biopsy needle and accessory development emphasized improved tissue acquisition and deployment control, with approximately 38% of advanced bronchoscopy programs evaluating accessory performance during equipment modernization.
• October 2025 – Navigation Workflow Integration: Advanced pulmonary centers expanded integration between bronchoscopy, imaging, and diagnostic planning, with approximately 35% of major thoracic oncology programs estimated to coordinate these functions within multidisciplinary workflows.
• March 2026 – Compact System Development: Manufacturers accelerated work on compact ultrasound processors and bronchoscopy platforms for space-constrained facilities, with approximately 26% of product-development activity focused on miniaturization or workflow simplification.
• August 2026 – Short-Stay Diagnostic Expansion: Selected Ambulatory Surgical Centers increased evaluation of EBUS-based diagnostic pathways, with approximately 12% of eligible procedures estimated to have potential for outpatient or short-stay management under appropriate clinical protocols.

Report Coverage

The Endobronchial Ultrasound Biopsy Market assessment covers EBUS-TBNA, Bronchoscopes and probes, Biopsy forceps and needles, Ultrasound processor and needles, Cytology brushes and spray catheter, and Others. Applications analyzed include Hospitals, Specialty Centers, Diagnostic Centers, and Ambulatory Surgical Centers. The market evaluation covers the 2026 to 2035 period and examines demand drivers, technological development, procedural adoption, equipment modernization, biopsy accessory consumption, healthcare infrastructure, specialist availability, and changing diagnostic workflows.

The regional assessment includes North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World. Competitive coverage includes Conmed Corporation, Medtronic plc, Olympus Corporation, Fujifilm Corporation, Boston Scientific Corporation, Pentax Medical, Cook Medical, Veran Medical Technologies, Medi-Globe GmbH, and Clinodevice. The assessment also evaluates product innovation, image-guided diagnostics, ultrasound processor development, biopsy needle improvements, navigation-assisted procedures, hospital investment, specialty-center expansion, and the gradual adoption of EBUS technologies across decentralized diagnostic environments through 2035.

Endobronchial Ultrasound Biopsy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 726.19 Million in 2026
Market Size Value By	USD 1442.02 Million by 2035
Growth Rate	CAGR of 7.92% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : EBUS-TBNA Bronchoscopes and probes Biopsy forceps and needles Ultrasound processor and needles Cytology brushes and spray catheter Others By Application : Hospitals Specialty Centers Diagnostic Centers Ambulatory Surgical Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample